Clinical trials: Lewy Body Disease, active
Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
This study is being done to research the usefulness of PET/CT imaging for measuring brain inflammation and its relation to Alzheimer's Disease Dementia and related dementias.
- Trial name
- NCT04786223
- Testing
- C-11 ER-176, Blood Test
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Val Lowe
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Parkinson Disease (PD)
Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution
Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various bodily systems.
- Trial name
- VaMPiRE (NCT06941012)
- Testing
- Blood draw for the laboratory assessment
- Where
- 4 sites in Greece, Italy and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Casa di Cura IGEA
Small Cell Lung Cancer
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body.
- Trial name
- NCT04624204
- Testing
- Pembrolizumab 200 mg, Pembrolizumab 400 mg, Olaparib 300 mg BID
- Where
- 187 sites in United States, Australia and 23 more
- Volunteers
- 672 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, FTD
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and…
- Conditions
- Alzheimer Disease, FTD, Young-onset Dementia, MCI
- Trial name
- NeurOmics (NCT07235111)
- Where
- Italy
- Volunteers
- 1,200 people
- Sponsor
- Ospedale Policlinico San Martino
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Lewy Body Disease, Lewy Body Dementia
Visual Hallucinations in Lewy Body Diseases
The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucinations in Lewy Body diseases to inform future treatment developments.
- Conditions
- Lewy Body Disease, Lewy Body Dementia, Parkinson Disease, Parkinson Disease Dementia
- Trial name
- NCT07849413
- Testing
- Behavioral Tasks, MRI/MEG Scans
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson Disease, REM Sleep Behavior Disorder
Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder
The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia…
- Conditions
- Parkinson Disease, REM Sleep Behavior Disorder, Dementia, Lewy Body
- Trial name
- NUK-RBD (NCT06629207)
- Testing
- PET/CT with 18-FDG, SPECT : 123 I-FP-CIT (DATSCAN), MRI
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Renal Cell Carcinoma
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the…
- Trial name
- INTerpath-004 (NCT06307431)
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 63 sites in United States, Argentina and 12 more
- Volunteers
- 272 people
- Sponsor
- Merck Sharp & Dohme LLC
Vascular Parkinsonism, Drug-induced Parkinsonism
AI-Enhanced Optimization of Acute Levodopa Challenge Test
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence.
- Conditions
- Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)
- Trial name
- NCT06949865
- Testing
- video recording
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Tiantan Hospital
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Head and Neck Neoplasms
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in…
- Trial name
- NCT03765918
- Testing
- Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray
- Where
- 192 sites in United States, Argentina and 22 more
- Volunteers
- 714 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
This multicenter study aims to characterize the language profiles of patients with various neurodegenerative diseases, including Alzheimer's disease (AD), Primary Progressive Aphasia (PPA), behavioral variant Frontotemporal…
- Conditions
- Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), Parkinsons Disease (PD), Lewy Body Dementia
- Trial name
- AILAN (NCT07906769)
- Testing
- Speech and language Test to support clinical diagnosis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Parkinson Disease, MSA - Multiple System Atrophy
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease
- Trial name
- EXTRAORDINARY (NCT06846658)
- Where
- 3 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with…
- Trial name
- NCT06032026
- Testing
- 11C-HY-2-15 PET, brain MRI, Amyloid PET scan
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dementia, Frontotemporal, Alzheimer Dementia (AD)
Investigating Genetic Status in Patients Presenting to Clinic
The causes of neurodegenerative dementias such as Frontotemporal Dementia, Lewy Body Disease and Alzheimer's disease are still largely unknown.
- Conditions
- Dementia, Frontotemporal, Alzheimer Dementia (AD), Lewy Body Dementia (LBD)
- Trial name
- NCT05911932
- Testing
- Biosample collection.
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts.
- Trial name
- NCT06483334
- Testing
- Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Lewy Body Disease
Longitudinal Imaging Biomarkers of Disease Progression in DLB
The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.
- Trial name
- NCT03582488
- Testing
- 18F-Flortaucipir
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- Kejal Kantarci
Metastatic Solid Tumors, Advanced Solid Tumors
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically…
- Trial name
- NCT05853367
- Testing
- MK-0472, Pembrolizumab, MK-1084
- Where
- 25 sites in United States, Canada and 5 more
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC